Why oral semaglutide needs an absorption enhancer at all posts 31–60

Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.

The claim is narrower than it sounds, and deliberately so.

The arithmetic in post #43 is right; the assumption feeding it is the part to check.

The version of oral semaglutide that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.

Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.

Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.

Nothing to add, except that this is the answer I would give if asked.

Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.

Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.

That is the version I use. It may not be the version that is correct.

Good question, well framed, and I would like to see it answered properly.

Taking post #50 at face value and following it one step further.

Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.

Post #53 and I disagree about the size of the effect, not about the direction.

Two claims get bundled together under oral semaglutide and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.

Almost every disagreement in threads like this one dissolves once you say which of the two you are making.

Excipients are not inert from an analytical point of view. A certificate for a formulated tablet has to account for them, and one that reports a purity figure without saying what the figure is a proportion of is ambiguous.

Building on post #54 rather than restating it.

Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.

Take the reasoning and check the arithmetic; I do not always get it right.

Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.

The honest answer is that it depends, and here is what it depends on.

Thank you for taking the time. That was more work than a reply usually is.

Coming back to post #56, because the follow-up matters more than the original answer.

Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.